You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,724,349

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,724,349

Title:	Methods for the treatment of HER2 amplified cancer
Abstract:	Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
Inventor(s):	Chen; Jun (San Jose, CA), Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA)
Assignee:	Pharmacyclics LLC (Sunnyvale, CA)
Application Number:	15/198,694
Patent Claims:	1. A method for treating HER2 amplified cancer in an individual in need thereof, wherein the cancer is selected from the group consisting of endometrial, cervical, urothelial, ovarian, gastric, gastroesophageal junction (GEJ), head and neck, biliary tract, and prostate cancers, and the method comprises administering to the individual in need thereof a composition comprising (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)prop-2-en-1-one ##STR00018## Ibrutinib, or a pharmaceutically acceptable solvate or pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the composition comprises ibrutinib. 3. The method of claim 1, wherein the HER2-amplified cancer is metastatic. 4. The method of claim 1, wherein the HER2-amplified cancer has a HER2:CEP17 ratio of 2.2-4.0 or >4.0. 5. The method of claim 1, wherein the HER2-amplified cancer is refractory to treatment. 6. The method of claim 1, further comprising co-administering an additional therapeutic agent. 7. The method of claim 6, wherein the additional therapeutic agent is an anti-HER2 therapeutic agent, a pan-ErbB inhibitor, or an anti-VEGF therapeutic agent. 8. The method of claim 7, wherein the anti-HER2 therapeutic agent is selected from the group consisting of: trastuzumab, trastuzumab emtansine, pertuzumab, lapatinib, and MM-111. 9. The method of claim 7, wherein the pan-ErbB inhibitor is selected from the group consisting of: afatinib, neratinib, and dacomitinib. 10. The method of claim 7, wherein the anti-VEGF therapeutic agent is selected from the group consisting of: bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, and pazopanib. 11. The method of claim 6, wherein the additional therapeutic agent is selected from the group consisting of: temsirolimus; paclitaxel; ASLAN001; vorinostat; doxorubicin; cyclophosphamide; cisplatin; docetaxel; dasatinib; trastuzumab and docetaxel; pertuzumab and docetaxel; doxorubicin, cyclophosphamide and paclitaxal; and doxorubicin, cyclophosphamide and 5-FU.

Details for Patent 9,724,349

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2033-08-12
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2033-08-12
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2033-08-12
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006	⤷ Try a Trial	2033-08-12
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012	⤷ Try a Trial	2033-08-12
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016	⤷ Try a Trial	2033-08-12
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.